Lead
For a long time, the standard pattern for managing atopic dermatitis was: flare up, apply topical steroid, improve, stop. Many parents, anxious about corticosteroid use, were inclined to stop as soon as visible symptoms cleared. This reactive approach seemed reasonable.
The problem is that it doesn't work well. Skin inflammation persists below the surface even after the rash appears to clear, and stopping topical treatment reliably leads to relapse — and then another round of the same cycle. Current evidence-based management has shifted to a "proactive" approach: continuing intermittent application to previously affected areas even after visible remission, specifically to prevent relapse rather than merely respond to it [6].
The Pathophysiology: Skin Barrier and the Inflammatory Loop
At the root of atopic dermatitis is a defect in the skin barrier. In 2006, loss-of-function variants in the filaggrin: a structural skin protein that helps form the outer barrier and retain moisture; mutations in its gene are a major genetic risk factor for eczema gene (FLG) — which encodes a structural protein essential to the epidermal barrier — were identified as a major risk factor for atopic dermatitis [5]. Filaggrin deficiency reduces the skin's capacity to retain water and allows external antigens (food proteins, dust mite allergens) to penetrate more easily, a process called transcutaneous sensitization.
In this setting, a Th2-skewed immune response drives persistent inflammation. Itch disrupts sleep; scratching damages the skin further. In apparent remission, the embers of inflammation can remain active below the surface.
What Proactive Therapy Is
Proactive therapy reframes how topical corticosteroids are used.
Reactive therapy (conventional approach): Apply topical corticosteroid when the skin flares. Stop when it clears. Flare again. Repeat.
Proactive therapy: Treat the acute flare as before. After the skin visibly settles, continue applying the corticosteroid to previously affected sites two to three times per week, on an ongoing basis.
In a 2003 randomized controlled trial, Berth-Jones et al. found that twice-weekly fluticasone propionate application reduced relapse rates by more than 70% compared with placebo [6]. Randomized trials of proactive therapy using topical calcineurin inhibitors (tacrolimus, pimecrolimus) have shown comparable relapse-reduction effects.
Japan's Atopic Dermatitis Clinical Practice Guideline 2021, published by the Japanese Dermatological Association, endorses proactive therapy as the standard of care [2].
Addressing Steroid Anxiety
"Is it safe to keep applying a corticosteroid for this long?" is a reasonable question. The adverse effects of topical corticosteroids — skin atrophy, striae, telangiectasia — occur when a product of excessive potency is applied to too large an area for too long a continuous period. Twice-weekly intermittent application is fundamentally different in character from continuous daily application [2].
For infants and young children, the guideline's basic principle is to use a lower-potency product (Weak to Medium class) on the face and areas of thin skin [2]. The common assumption that "applying thinly is safer" is not entirely accurate — the important variables are the right potency, the right quantity, and the right frequency. If there is uncertainty about any of these, a direct conversation with a dermatologist about which areas to treat, at what potency, and at what frequency is more useful than making adjustments unilaterally.
Moisturization and Biologics
Moisturizers are the foundation of treatment. Applying a moisturizer twice daily — ideally within three minutes of bathing — is recommended throughout management. Moisturizers do not have anti-inflammatory properties, but by reinforcing the skin barrier they reduce antigen penetration and transcutaneous sensitization [1].
Dupilumab: an injectable biologic medication that blocks specific immune signals (IL-4 and IL-13) driving allergic inflammation; used for moderate-to-severe eczema and other allergic diseases, a biologic agent that blocks the receptor for Th2 cytokines (IL-4 and IL-13), has an established efficacy record in moderate-to-severe atopic dermatitis. Although adult use came first, it is now approved in Japan for patients aged six months and older, and is an option for severe cases that cannot be adequately controlled with topical treatment [2].
Translating Evidence into Everyday Decisions
- Daily moisturizing: Apply to the whole body within three minutes of bathing. Continue even when the skin looks clear — this is a treatment foundation, not a reactive measure
- Proactive application: When instructed by a physician, "continue applying two to three times a week to the areas that were affected, even after they look better" is the key point
- Verify potency instructions: Confirm that the prescribed product comes with clear guidance on which areas to apply it to and in what quantity
- Track flare patterns: Noting which areas worsen, in what seasons, and under what environmental conditions in a parenting log gives the dermatologist specific information to adjust treatment
Summary
Managing atopic dermatitis has shifted from "stop when it clears" to "maintain twice or three times a week after it clears." Proactive therapy is a method for reducing flare frequency — it is not about increasing total corticosteroid use but about applying the right amount, at the right frequency, to the right areas. That distinction matters both for effectiveness and for managing reasonable concerns about long-term steroid use.
Related Articles
- 237 Infant Eczema, Seborrheic Dermatitis, and Atopic Dermatitis: Telling Them Apart — The three common infant skin conditions: distinguishing features and the case for early moisturizing
- 240 Food Allergy: First Symptoms and Emergency Response — Food allergy onset risk in children with eczema, and the evidence for early introduction
- 242 The Dual Allergen Exposure Hypothesis — Why treating eczema early may also prevent food allergy
References
- Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824–830.e6. doi:10.1016/j.jaci.2014.07.060. PMID: 25282564.
- Japanese Dermatological Association. Guidelines for the Management of Atopic Dermatitis 2021. Jpn J Dermatol. 2021;131(13):2691–2777.
- Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology. J Am Acad Dermatol. 2004;50(3):391–404. doi:10.1016/j.jaad.2003.08.048. PMID: 14988682.
- Schmitt J, Schmitt NM, Kirch W, Meurer M. Early exposure to antibiotics and infections and the incidence of atopic eczema. Pediatr Allergy Immunol. 2010;21(2):292–300. doi:10.1111/j.1399-3038.2009.00896.x. PMID: 19490508.
- Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi:10.1038/ng1767. PMID: 16550169.
- Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;326(7403):1367. doi:10.1136/bmj.326.7403.1367. PMID: 12816823.